^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EC-70124

    i
    Other names: EC-70124, EC70124, EC 70124
    Company:
    EntreChem
    Drug class:
    mTOR inhibitor, JAK2 inhibitor, FLT3 inhibitor, AKT inhibitor, SYK inhibitor, STAT3 inhibitor, NF-κB inhibitor, PIM inhibitor, STAT5 inhibitor, IKKe inhibitor, RPS6 inhibitor
    Related drugs:
    2years
    The Multi-Kinase Inhibitor EC-70124 Is a Promising Candidate for the Treatment of FLT3-ITD-Positive Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
    Several tyrosine kinase/FLT3 inhibitors have been developed and tested clinically, but very few (midostaurin and gilteritinib) have thus far been FDA/EMA-approved for patients with newly diagnosed or relapse/refractory FLT3-ITD AML. Orally disposable EC-70124 exerted a potent inhibitory effect on the growth of FLT3-ITD AML cells, delaying disease progression and debulking the leukemia. Collectively, our findings show that EC-70124 is a promising and safe agent for the treatment of AML with FLT3-ITD.
    Journal
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    Xospata (gilteritinib) • Rydapt (midostaurin) • EC-70124